Table 2.
Activity of PD1/PD-L1 inhibitors in combination with targeted therapies (PARP inhibitors, anti-angiogenic or other ICIs) in relapsed OC.
| ICI combo | Phase | N | Indication | RR (%) | PFS | Ref |
|---|---|---|---|---|---|---|
| ICI + PARP inhibitor | ||||||
| Durvalumab + olaparib | I/II | 32 | PSOC BRCAm | 72 | 11 mo | Drew et al.36 |
| 32 | PSOC BRCAwt | 34 | NA | Liu et al.44 | ||
| Pembrolizumab + niraparib | I/II | 62 | PROC or platinum ineligible 80% BRCAwt | 18 | NA | Konstantinopoulos et al.39 |
| ICI + VEGF inhibitor | ||||||
| Durvalumab + cediranib | I | 12 | Recurrent OC | 50 | NA | Lee et al.43 |
| Nivolumab + bevacizumab | II | 38 | Recurrent OC | 29 | 8 mo | Liu et al.44 |
| - PROC (N = 18) | 40 | |||||
| - PSOC (N = 20) | 17 | |||||
| Pembrolizumab + lenvatinib | II | 31 | Recurrent OC | 32 | NA | Lwin et al.46 |
| Carbo/Pac + bevacizumab + atezolizumab versus placebo | III | 1301 | 1st line advanced OC | NA | 19.5 mo versus 18.4 p:NS | Moore et al.49 |
| ICI + PARP inhibitor + VEGF inhibitor | ||||||
| Durvalumab + olaparib + bevacizumab | I/II | 32 | PSOC BRCAwt | 87 | NA | Liu et al.44 |
| ICI + ICI | ||||||
| Nivolumab + ipilimumab versus placebo | II | 100 | Recurrent OC PFI < 12 mo | 31 versus 12 | 3.9 mo versus 2 mo | Zamarin et al.53 |
ICI, immune checkpoint inhibitor; OC, ovarian cancer; PARP, poly(ADP-ribose) polymerase; PD1, Programmed cell death protein 1; PD-L1, Programmed death ligand 1; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PROC, platinum resistant ovarian cancer; PSOC, platinum sensitive ovarian cancer; RR, response rate; VEGF, vascular endothelial growth factor.